Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis

被引：0
|
作者：
Donze, C. [1 ]
Guyot, M. A. [1 ]
Kwiatkowski, A. [2 ]
Hautecoeur, P. [2 ]
Massot, C. [1 ]
机构：
[1] Inst Catholique Lille, Grp Hosp, Rehabil, Lille, France
[2] Inst Catholique Lille, Grp Hosp, Neurol, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P756
引用
收藏
页码：385 / 385
页数：1
相关论文
共 50 条
  • [21] Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: 48-month follow-up data
    De Seze, J.
    Edan, G.
    Moreau, T.
    Brochet, B.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 287 - 288
  • [22] MD1003 (High-Dose Biotin) for the treatment of progressive multiple sclerosis: baseline data and results from a cohort of patients included in a early access program
    Brassat, D.
    Hautecoeur, P.
    Durand-Dubief, F.
    Castelnovo, G.
    Derache, N.
    Bourre, B.
    Le Page, E.
    Donze, C.
    Audoin, B.
    Ouallet, J-C.
    Collongues, N.
    Simon, O.
    Brion, G.
    Vermersch, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 936 - 937
  • [23] Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months
    De Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Sedel, Frederic
    Tourbah, Ayman
    [J]. NEUROLOGY, 2019, 92 (15)
  • [24] NFL pattern in progressive Multiple Sclerosis cohort under MD1003 treatment
    Pignolet, Beatrice
    Ammoscato, Francesca
    Ciron, Jonathan
    Bucciarelli, Florence
    Scandella, Lise
    Biotti, Damien
    Lerebours, Fleur
    Dorcet, Guillaume
    Rabadeux, Celine
    Freitas, Noellie
    Bonneville, Fabrice
    Gnanapavan, Sharmilee
    Brassat, David
    [J]. NEUROLOGY, 2019, 92 (15)
  • [25] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores
    Papeix, C.
    Lebrun-Frenay, C.
    Defer, G.
    Labauge, P.
    Ruiz, M.
    Simon, O.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 938 - 939
  • [26] Efficacy and safety results of the phase 3 SPI2 study of MD1003 (high dose Pharmaceutical grade Biotin) in progressive MS
    Cree, B. A. C.
    Cutter, G.
    Wolinsky, J. S.
    Freedman, M. S.
    Comi, G.
    Giovannoni, G.
    Hartung, H. -P.
    Sedel, F.
    Lublin, F.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 46 - 46
  • [27] Effect of MD1003 (high dose pharmaceutical grade biotin) in progressive MS: design and baseline data from the phase III SPI2 study
    Cree, B. A. C.
    Cutter, G.
    Wolinsky, J. S.
    Freedman, M. S.
    Comi, G.
    Giovannoni, G.
    Hartung, H. P.
    Sedel, F.
    Lublin, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 692 - 693
  • [28] MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial
    Tourbah, A.
    Lebrun-Frenay, C.
    Edan, G.
    Clanet, M.
    Papex, C.
    Vukusic, S.
    De Sesze, J.
    Debouverie, M.
    Gout, O.
    Clavelou, P.
    Defer, G.
    Laplaud, D.
    Moreau, T.
    Labauge, P.
    Brochet, B.
    Sedel, F.
    Pelletier, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 785 - 785
  • [29] MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
    Tourbah, Ayman
    Lebrun-Frenay, Christine
    Edan, Gilles
    Clanet, Michel
    Papeix, Caroline
    Vukusic, Sandra
    De Seze, Jerome
    Debouverie, Marc
    Gout, Olivier
    Clavelou, Pierre
    Defer, Gilles
    Lapland, David-Axel
    Moreau, Thibault
    Labauge, Pierre
    Brochet, Bruno
    Sedel, Frederic
    Pelletier, Jean
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (13) : 1719 - 1731
  • [30] Effects of high dose pharmaceutical grade biotin (MD1003), on survival, ensheathment, and ATP production by oligodendrocyte lineage cells in vitro
    Cui, Q. -L.
    Lin, Y. H.
    Xu, Y. K. T.
    Rao, V. T.
    Perdomini, M.
    Bernard, D.
    Antel, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 676 - 676
12345